Linda Marbán
Principal executive officer pay for Linda Marbán, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
CAPRICOR THERAPEUTICS, INC. (CAPR) FY2021–FY2025
Aligned: paid up as stock roseCAP $1,153,255→$7,230,676 while $100 invested went $85.00→$748.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $1.8M | $1.2M |
| FY2022 | $1.3M | $2.2M |
| FY2023 | $774,300 | $1.2M |
| FY2024 | $1.5M | $5.1M |
| FY2025 | $3.5M | $7.2M |
The company's "$100 invested" index ran $85.00 at FY2021 → $748.00 by FY2025 — an annualized return of 72.2%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 72.2%/yr at CAPR ( FY2021–FY2025). See the CEO track-record ranking for context.